Could the Oxidation of α1-Antitrypsin Prevent the Binding of Human Neutrophil Elastase in COVID-19 Patients?
Maura D'AmatoMonica CampagnoliPaolo IadarolaPaola Margherita BignamiMarco FumagalliLaurent Roberto ChiarelliGiovanni StelitanoFederica MeloniPasquale LincianoSimona CollinaGiampiero PietrocolaValentina VertuiAnna AlibertiTommaso FossaliSimona ViglioPublished in: International journal of molecular sciences (2023)
Human neutrophil elastase (HNE) is involved in SARS-CoV-2 virulence and plays a pivotal role in lung infection of patients infected by COVID-19. In healthy individuals, HNE activity is balanced by α1-antitrypsin (AAT). This is a 52 kDa glycoprotein, mainly produced and secreted by hepatocytes, that specifically inhibits HNE by blocking its activity through the formation of a stable complex (HNE-AAT) in which the two proteins are covalently bound. The lack of this complex, together with the detection of HNE activity in BALf/plasma samples of COVID-19 patients, leads us to hypothesize that potential functional deficiencies should necessarily be attributed to possible structural modifications of AAT. These could greatly diminish its ability to inhibit neutrophil elastase, thus reducing lung protection. The aim of this work was to explore the oxidation state of AAT in BALf/plasma samples from these patients so as to understand whether the deficient inhibitory activity of AAT was somehow related to possible conformational changes caused by the presence of abnormally oxidized residues.
Keyphrases
- sars cov
- end stage renal disease
- endothelial cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- coronavirus disease
- escherichia coli
- pseudomonas aeruginosa
- staphylococcus aureus
- respiratory syndrome coronavirus
- risk assessment
- nitric oxide
- induced pluripotent stem cells
- quantum dots
- binding protein
- antimicrobial resistance
- label free